Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 3:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–17 of 17 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Orbactiv Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Cardiac Safety of Oritavancin in Healthy Participants

NCT01762839
View directory record Official record
Conditions
Healthy
Interventions
Single-Dose IV Oritavancin Diphosphate, Placebo, Moxifloxacin
Drug
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 31, 2024 · Synced Sep 7, 2026, 3:19 AM EDT
Terminated Phase 4 Interventional Results available

Comparing Oral Versus Parenteral Antimicrobial Therapy

NCT05977868
View directory record Official record
Conditions
Endovascular Infection, Bone and Joint Infection, Skin and Soft Tissue Infection, Pulmonary Infection, Gastrointestinal Infection, Genitourinary Infection
Interventions
Amoxicillin, amoxicillin-clavulanate, cefadroxil, cefpodoxime, cefalexin, ciprofloxacin, delafloxacin, doxycycline, levofloxacin, linezolid, Ampicillin, ampicillin-sulbactam, cefazolin, cefepime, ceftaroline, ceftazidime, ceftazidime-avibactam, dalbavancin, daptomycin, ertapenem
Drug
Lead sponsor
West Virginia University
Other
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Aug 25, 2025 · Synced Sep 7, 2026, 3:19 AM EDT
Completed Phase 1 Interventional Results available

Relative Exposure and Safety Study of Kimyrsa in ABSSSI Patients

NCT03873987
View directory record Official record
Conditions
Acute Bacterial Skin and Skin Structure Infection
Interventions
Current Formulation of Oritavancin, Kimyrsa
Drug
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
4
States / cities
Chula Vista, California • La Mesa, California • Burr Ridge, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2021 · Synced Sep 7, 2026, 3:19 AM EDT
Withdrawn Phase 4 Interventional

Oritavancin for Staphylococcus Aureus Infections in Opioid Users

NCT03761953
View directory record Official record
Conditions
Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Endocarditis
Interventions
Oritavancin Injection
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 5, 2022 · Synced Sep 7, 2026, 3:19 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety, Tolerability and Pharmacokinetics of a New Formulation of Oritavancin in Healthy Volunteers

NCT02471690
View directory record Official record
Conditions
Healthy
Interventions
Oritavancin, Dextrose
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 18, 2023 · Synced Sep 7, 2026, 3:19 AM EDT
Completed Phase 1 Interventional

Open Label, Dose-finding, Pharmacokinetics, Safety and Tolerability Study of Oritavancin in Pediatric Participants With Suspected or Confirmed Bacterial Infections

NCT02134301
View directory record Official record
Conditions
Gram-positive Bacterial Infections
Interventions
Oritavancin
Drug
Lead sponsor
Melinta Therapeutics, LLC
Industry
Eligibility
Up to 18 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
8
States / cities
Little Rock, Arkansas • Orange, California • San Diego, California + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Sep 7, 2026, 3:19 AM EDT
Completed Phase 3 Interventional Results available

Oritavancin Versus IV Vancomycin for the Treatment of Participants With Acute Bacterial Skin and Skin Structure Infection (SOLO I)

NCT01252719
View directory record Official record
Conditions
Wound Infection, Abscess, Systemic Inflammation, Cellulitis
Interventions
Single-Dose IV Oritavancin Diphosphate, IV Vancomycin, Placebo
Drug
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
968 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jul 31, 2022 · Synced Sep 7, 2026, 3:19 AM EDT
Completed Phase 2 Interventional

Study to Evaluate the Safety of Intravenous Oritavancin for the Treatment of Children With Skin Infections

NCT05599295
View directory record Official record
Conditions
Acute Bacterial Skin and Skin Structure Infection
Interventions
Orbactiv, Kimyrsa
Drug
Lead sponsor
Melinta Therapeutics, LLC
Industry
Eligibility
3 Months to 11 Years
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Tampa, Florida • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Sep 7, 2026, 3:19 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Open Label Study Evaluating the Effects of a Single Oritavancin Infusion on Cytochrome P450 in Healthy Volunteers

NCT01784536
View directory record Official record
Conditions
Healthy
Interventions
Single-Dose IV Oritavancin Diphosphate
Drug
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 18, 2023 · Synced Sep 7, 2026, 3:19 AM EDT
Completed Phase 4 Interventional Results available

Safety of Either a Single or Two Intravenous Doses of Orbactiv in Participants With Acute Bacterial Skin and Skin Structure Infection

NCT02925416
View directory record Official record
Conditions
Skin Diseases, Bacterial
Interventions
Oritavancin, Placebo (D5W)
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Somers Point, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 31, 2024 · Synced Sep 7, 2026, 3:19 AM EDT
Completed Phase 2 Interventional

A Study for Patients With Complicated Skin and Skin Structure Infections

NCT00514527
View directory record Official record
Conditions
Staphylococcal Skin Infections, Wounds and Injuries, Abscess, Cellulitis, Streptococcal Infections
Interventions
oritavancin
Drug
Lead sponsor
Targanta Therapeutics Corporation
Industry
Eligibility
18 Years and older
Enrollment
294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
33
States / cities
Mobile, Alabama • Anaheim, California • Buena Park, California + 29 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2008 · Synced Sep 7, 2026, 3:19 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Multiple Oritavancin Doses on Safety, Tolerability, and Pharmacokinetics in Healthy Subjects

NCT02470702
View directory record Official record
Conditions
Healthy
Interventions
Oritavancin, Placebo (D5W)
Drug
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 18, 2023 · Synced Sep 7, 2026, 3:19 AM EDT
Completed Phase 3 Interventional Results available

Oritavancin Versus IV Vancomycin for the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infection

NCT01252732
View directory record Official record
Conditions
Wound Infection, Abscess, Systemic Inflammation, Cellulitis
Interventions
Single-Dose IV Oritavancin Diphosphate, IV Vancomycin
Drug
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,019 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
La Mesa, California
Source: ClinicalTrials.gov public record
Updated May 4, 2021 · Synced Sep 7, 2026, 3:19 AM EDT
Completed No phase listed Observational

A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Orbactiv® (Oritavancin) for Infections Caused by Gram Positive Bacteria in a Real World Setting

NCT03159403
View directory record Official record
Conditions
Gram-Positive Bacterial Infections
Interventions
Oritavancin
Drug
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
Not listed
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
21
States / cities
Birmingham, Alabama • Santa Barbara, California • Fort Myers, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2018 · Synced Sep 7, 2026, 3:19 AM EDT
Terminated Phase 4 Interventional Results available

Anchoring Sequential Intermittent Long Acting Antimicrobials With Medication for Opioid Use Disorder (MOUD) for Invasive Infections Related to Opioid Use

NCT05521880
View directory record Official record
Conditions
Substance Use Disorders, Infection, Soft Tissue, Bacteremia, Osteomyelitis Acute, Septic Arthritis
Interventions
Oritavancin
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 88 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 7, 2026, 3:19 AM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Safety of a Single Intravenous (IV) Dose of Orbactiv (Oritavancin) in Participants on Chronic Warfarin Therapy Being Treated For Acute Bacterial Skin and Skin Structure Infection (ABSSSI)

NCT02452918
View directory record Official record
Conditions
Acute Bacterial Skin and Skin Structure Infection
Interventions
Oritavancin, Warfarin
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Somers Point, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 19, 2023 · Synced Sep 7, 2026, 3:19 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction Potential of Orbactiv (Oritavancin) Co-Administered With Warfarin in Healthy Subjects

NCT02340988
View directory record Official record
Conditions
Healthy
Interventions
Single-Dose IV Oritavancin Diphosphate and Warfarin, Single-Dose IV Oritavancin Diphosphate and Warfarin 24 hour post dose
Drug
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 18, 2023 · Synced Sep 7, 2026, 3:19 AM EDT